{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:54:23Z","timestamp":1781826863615,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["ZLRK202302"],"award-info":[{"award-number":["ZLRK202302"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC0110904"],"award-info":[{"award-number":["2017YFC0110904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2015BAI13B09"],"award-info":[{"award-number":["2015BAI13B09"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202884"],"award-info":[{"award-number":["82202884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["1192070313"],"award-info":[{"award-number":["1192070313"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drup.2026.101384","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:55:31Z","timestamp":1772038531000},"page":"101384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR\/MSS patients with locally advance rectal cancer: A phase 2 clinical trial"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-9619","authenticated-orcid":false,"given":"Zhengyang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiagang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.drup.2026.101384_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.drup.2026.101384_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.drup.2026.101384_bib4","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","article-title":"Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921","volume":"23","author":"Bosset","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41392-025-02446-x","article-title":"Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.drup.2026.101384_bib6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.drup.2026.101384_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101384_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101285","article-title":"Emerging role of sialylation in cancer therapy resistance: mechanisms and therapeutic implications","volume":"83","author":"Farrell","year":"2025","journal-title":"Drug Resist Updat"},{"issue":"7","key":"10.1016\/j.drup.2026.101384_bib9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdy143","article-title":"Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO\/ARO\/AIO-04 randomized phase III trial","volume":"29","author":"Fokas","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.drup.2026.101384_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8+ T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"28","key":"10.1016\/j.drup.2026.101384_bib11","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203","volume":"24","author":"G\u00e9rard","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101384_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101250","article-title":"Targeting SLC7A11 with sorafenib sensitizes stereotactic body radiotherapy in colorectal cancer liver metastasis","volume":"81","author":"He","year":"2025","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101384_bib14","article-title":"Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment","volume":"7","author":"Li","year":"2024","journal-title":"Res."},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-025-04087-x","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study","volume":"23","author":"Lin","year":"2025","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.drup.2026.101384_bib16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.drup.2026.101384_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.drup.2026.101384_bib18","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1097\/JS9.0000000000002290","article-title":"Rectal cancer approach strategies after neoadjuvant treatment - a systematic review and network meta-analysis","volume":"111","author":"Meng","year":"2025","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.drup.2026.101384_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21197","article-title":"Pathologic complete response and survival in rectal cancer: a systematic review and meta-analysis","volume":"8","author":"Sugumar","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101384_bib22","article-title":"Inhibition of PCSK9: a promising enhancer for Anti-PD-1\/PD-L1 immunotherapy","volume":"7","author":"Sun","year":"2024","journal-title":"Res. (Wash. D. C. )"},{"key":"10.1016\/j.drup.2026.101384_bib23","article-title":"Radiomic model associated with tumor microenvironment predicts immunotherapy response and prognosis in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"8","author":"Sun","year":"2025","journal-title":"Res."},{"issue":"2","key":"10.1016\/j.drup.2026.101384_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41416-024-02730-7","article-title":"Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"131","author":"Tsukada","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.drup.2026.101384_bib25","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long-TErm Results of Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy: the Randomized Phase II OPRA trial","volume":"42","author":"Verheij","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.drup.2026.101384_bib26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The Reciprocity between Radiotherapy and Cancer Immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"28","key":"10.1016\/j.drup.2026.101384_bib27","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase ii trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.drup.2026.101384_bib28","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"10","key":"10.1016\/j.drup.2026.101384_bib30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.medj.2024.07.002","article-title":"Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer","volume":"5","author":"Yang","year":"2024","journal-title":"Med."},{"issue":"2","key":"10.1016\/j.drup.2026.101384_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","article-title":"Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial","volume":"31","author":"Yang","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101384_bib32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12885-022-09554-9","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.drup.2026.101384_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70011","article-title":"iMLGAM: integrated machine learning and genetic algorithm-driven multiomics analysis for pan-cancer immunotherapy response prediction","volume":"4","author":"Ye","year":"2025","journal-title":"Imeta"},{"issue":"3","key":"10.1016\/j.drup.2026.101384_bib34","article-title":"Long-Term Outcomes of dMMR\/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment","volume":"22","author":"Yu","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"7926","key":"10.1016\/j.drup.2026.101384_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101384_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101206","article-title":"Harnessing phytochemicals: innovative strategies to enhance cancer immunotherapy","volume":"79","author":"Zhu","year":"2025","journal-title":"Drug Resist Updat"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462600035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462600035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:27:25Z","timestamp":1781825245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876462600035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"alternative-id":["S136876462600035X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101384","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR\/MSS patients with locally advance rectal cancer: A phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101384"}}